KCNQ1 variants and response to repaglinide treatment in patients with Type 2 diabetes.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Pharmacogenomics (London)

• Publication date

  2012-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2217/pgs.12.115PMID 22966882
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2012cited by this paper
• KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese Type 2 diabetic patients

  2012cited by this paper
• Disposition of metformin: Variability due to polymorphisms of organic cation transporters

  2012cited by this paper
• KCNJ11 gene E23K variant and therapeutic response to sulfonylureas.

  2012cited by this paper
• Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A

  2012cited by this paper
• The role of ATM in response to metformin treatment and activation of AMPK.

  2012cited by this paper
• The role of ATM in response to metformin treatment and activation of AMPK

  2012cited by this paper
• A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts

  2012cited by this paper
• Variation in KCNQ1 is associated with therapeutic response to sulphonylureas

  2011cited by this paper
• A Common 5′‐UTR Variant in MATE2‐K Is Associated With Poor Response to Metformin

  2011cited by this paper
• Effects of KCNQ1 Polymorphisms on the Therapeutic Efficacy of Oral Antidiabetic Drugs in Chinese Patients With Type 2 Diabetes

  2011cited by this paper
• The Effect of Oral Antidiabetic Agents on A1C Levels

  2010cited by this paper
• Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes

  2010cited by this paper
• New Users of Metformin Are at Low Risk of Incident Cancer

  2009cited by this paper
• Genetic Variation in the Multidrug and Toxin Extrusion 1 Transporter Protein Influences the Glucose-Lowering Effect of Metformin in Patients With Diabetes: A Preliminary Study

  2009cited by this paper
• A Variant in the KCNQ1 Gene Predicts Future Type 2 Diabetes and Mediates Impaired Insulin Secretion

  2009cited by this paper
• Coexpression of the Type 2 Diabetes Susceptibility Gene Variants KCNJ11 E23K and ABCC8 S1369A Alter the ATP and Sulfonylurea Sensitivities of the ATP-Sensitive K+ Channel

  2009cited by this paper
• Variations in KCNQ1 are associated with type 2 diabetes and beta cell function in a Chinese population

  2009cited by this paper
• Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus

  2009cited by this paper
• Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus

  2008cited by this paper
• Ser1369Ala Variant in Sulfonylurea Receptor Gene ABCC8 Is Associated With Antidiabetic Efficacy of Gliclazide in Chinese Type 2 Diabetic Patients

  2008cited by this paper
• SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations

  2008cited by this paper
• The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.

  2008cited by this paper
• Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes.

  2007cited by this paper
• AICAR induces phosphorylation of AMPK in an ATM-dependent, LKB1-independent manner

  2007cited by this paper
• Effects of I(Ks) channel inhibitors in insulin-secreting INS-1 cells.

  2005cited by this paper
• Effects of IKs channel inhibitors in insulin-secreting INS-1 cells

  2005cited by this paper
• Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region.

  2004cited by this paper
• Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide

  2003cited by this paper
• The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes.

  2003cited by this paper
• Sulphonylurea action revisited: the post-cloning era

  2003cited by this paper
• Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias

  1996cited by this paper
• KvLQT1 and IsK (minK) proteins associate to form the IKS cardiac potassium current

  1996cited by this paper
• Ataxia-telangiectasia: an overview.

  1985cited by this paper
• Glucose induces closure of single potassium channels in isolated rat pancreatic β-cells

  1984cited by this paper
• Receptor binding sites of hypoglycemic sulfonylureas and related [(acylamino)alkyl]benzoic acids.

  1984cited by this paper
• An unusual form of diabetes mellitus in ataxia telangiectasia.

  1970cited by this paper

• Metformin and Chemoprevention: Potential for Heart-Healthy Targeting of Biologically Aggressive Breast Cancer

  2020cites this paper
• Metformin as an Adjunctive Therapy for Pancreatic Cancer: A Review of the Literature on Its Potential Therapeutic Use

  2018cites this paper
• A gene variant near ATM affects the response to metformin and metformin plasma levels: a post hoc analysis of an RCT.

  2018cites this paper
• Although ABCC 8 1369 Ala and KCNJ 11 23 K variants

  2018cites this paper
• Pharmacogenetics in type 2 diabetes: still a conundrum in clinical practice

  2017cites this paper
• Pharmacogenomics of Type 2 Diabetes Mellitus

  2017cites this paper
• Pharmacogenomics of Metformin- A Way to Personalised medicine

  2016cites this paper
• Metformin Pharmacogenomics: Biomarkers to Mechanisms

  2014cites this paper
• Metformin Pharmacogenomics: Current Status and Future Directions

  2014cites this paper
• Blood DNA methylation biomarkers for breast cancer risk

  2013cites this paper